在宫癌放射治疗中以β-西托斯特醇向铁死
Yuanyuan Xiao1, Yuanqin Zhao2,3, Zhenlei Wang4
1Hunan Key Laboratory of Typical Environment Pollution and Health Hazards, College of Public Health, Hengyang Medical School, University of South China, Hengyang, 421001, P.R. China.
Current medicinal chemistry
|January 26, 2026
概括
这篇评论强调了β-固醇如何通过诱导细胞死亡途径铁亡来增强宫癌放射治疗. 这种方法克服了放射电阻,改善了治疗结果.
科学领域:
- 在瘤学瘤学.
- 生物化学 生物化学
- 放射疗法是一种放射治疗.
背景情况:
- 放射电阻是宫癌治疗的一个主要挑战,限制了放射治疗 (RT) 的疗效.
- 铁,一种依赖于铁的细胞死亡形式,是克服放射电阻的潜在策略.
研究的目的:
- 探索铁化在增强宫癌放射治疗疗效方面的作用.
- 通过GPX4/ACSL4轴研究β-固醇的放射敏感化作用.
主要方法:
- 对临床前模型和关于癌症中铁亡的现有文献的审查.
- 分析β-固醇向线粒体膜,GPX4和ACSL4.4的机制.
- 预测生物标志物的评估,如ox-LDL和ACSL4 / GPX4比率.
主要成果:
- 通过抑制GPX4和激活ACSL4,促进铁亡,β-醇使瘤对放射治疗敏感.
- 临床前研究表明β-固醇增强RT敏感性,增加瘤铁积累.
- 建议使用ox-LDL和ACSL4 / GPX4比率的预测框架用于临床应用.
结论:
- 乙-固醇有望通过诱导铁亡来克服宫癌中的放射电阻.
- 进一步研究铁 - 亡相互作用,微生物群和人工智能驱动的组合可以优化个性化的RT策略.
相关概念视频
Targeted Cancer Therapies
8.9K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
8.9K
TGF - β Signaling Pathway
10.5K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.5K
Adrenergic Receptors: β Subtype
3.7K
β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
3.7K
Antianginal Drugs: Nitrates and β-Blockers
1.6K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.6K
Antihypertensive Drugs: Types of β-Blockers
1.6K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.6K
Heart Failure Drugs: β-Blockers
886
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
886


